Dimitris J Richter*
Head of Cardiac Department, Euroclinic Hospital, Athens, Greece
*Corresponding Author: Head of Cardiac Department, Euroclinic Hospital, Athens, Greece
Received: March 29, 2020; Published: May 31, 2020
Leaving in the Corona-virus era, brings a lot of digital innovations including the first LBCT presentation virtually. The Victoria  study presented virtually at ACC 2020 and published simultaneously at NEJM presented the results of verisiguat, a novel oral soluble guanylate cyclase stimulator, that enhances the cyclic guanosine monophosphate (GMP) pathway by directly stimulating soluble guanylate cyclase through a binding site independent of nitric oxide, and it sensitizes soluble guanylate cyclase to endogenous nitric oxide by stabilizing nitric oxide binding to the binding site .
Citation: Dimitris J Richter. “Verisiguat: A New Kid in Town. But One Size does not Fit all Heart Failure". Acta Scientific Medical Sciences 4.6 (2020): 145-146.
Copyright: © 2020 Dimitris J Richter. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.